3715: Is Retatrutide Better Than Ozempic? (WW)

In this episode of The Cabral Concept, Dr. Stephen Cabral examines the emerging drug retatrutide in comparison to the well-known GLP-1 medication Ozempic. While both drugs aid in weight loss by targeting appetite and blood sugar regulation, retatrutide stands out as a 'triple agonist'—activating GLP-1, GIP, and glucagon pathways—potentially leading to greater fat loss and metabolic benefits. Initial clinical trials suggest retatrutide may offer around 23–24% weight loss over 68 weeks, slightly higher than Ozempic’s 21%, though the difference is modest. However, retatrutide comes with more significant side effects, including 18% discontinuation rates, diarrhea in 34% of users, and a concerning 21% reporting painful skin sensations. Dr. Cabral emphasizes caution, noting that retatrutide is not yet FDA-approved and lacks long-term safety data, especially regarding potential heart-related risks. In contrast, Ozempic is more established, predictable, and better studied, despite its own side effects like gastrointestinal distress and possible thyroid concerns. Dr. Cabral concludes that while retatrutide appears more potent on paper, Ozempic remains the safer, more responsible choice for now—especially when paired with lifestyle changes like strength training and high protein intake. He urges listeners to avoid long-term dependency on these drugs and instead use them as temporary tools within a holistic health plan. Key takeaways include: 1) Retatrutide is a triple agonist with greater theoretical weight loss potential than Ozempic; 2) The actual weight loss difference is only 2–3%, not the often-cited 21%+; 3) Retatrutide has significantly higher discontinuation rates due to side effects like diarrhea and painful skin sensitivity; 4) Both drugs risk muscle and bone loss, which can worsen metabolism long-term; 5) Ozempic remains the safer, better-studied option for now; 6) Long-term success requires combining pharmaceuticals with strength training, protein intake, and natural health strategies; 7) Clinical trials for retatrutide are still ongoing—patience is advised; 8) Never use these drugs without a clear plan to transition back to natural health practices.